Validation of SARS-CoV-2 (2019nCoV) codon-optimized (CO) Spike overexpression in HEK293 cell line by GeneMedi's adenoviral and lentiviral vectorpdf downloadPost Download

Picture loading failed.
Figure. Validation of SARS-CoV-2 (2019nCoV) codon optimized (CO) Spike expression in HEK293 cell line by GeneMedi's adenoviral vector (GMV-V-2019nCoV-053, GMV-V-2019nCoV-047) and lentiviral vector (GMV-V-2019nCoV-051) with Immunofluorescence (left) and Western Blot (right) by FLAG antibody.

Collection of COVID-19 landscape knowledge base


Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine - A landscape for vaccine technology against infectious disease, COVID-19 and tumor.

COVID-19 landscape Knowledge Base



1. Wu, A. et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe, doi:10.1016/j.chom.2020.02.001 (2020).




GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy